Italia markets open in 8 hours 17 minutes

Aclaris Therapeutics, Inc. (0H8T.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,3550+0,0100 (+0,74%)
Alla chiusura: 07:03PM BST
Schermo intero
Chiusura precedente1,3450
Aperto1,4700
Denaro0,0000 x N/D
Domanda0,0000 x N/D
Min-Max giorno1,3550 - 1,7200
Intervallo di 52 settimane0,6052 - 10,8700
Volume75.693
Media Volume12.279
Capitalizzazione39,624M
Beta (mensile su 5 anni)0,28
Rapporto PE (ttm)N/D
EPS (ttm)-1,3600
Prossima data utili05 ago 2024 - 09 ago 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

    - Top-line Data Anticipated Around Year End WAYNE, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the completion of enrollment into ATI-1777-AD-202, its Phase 2b trial of its investigational topical “soft” Janus kinase (JAK) 1/3 inhibitor, ATI-1777, in patients with mild to severe atopic dermatitis. Aclaris anticipates releasi

  • GlobeNewswire

    Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

    WAYNE, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 10:30 AM ET, in New York, NY. A webcast of the fireside chat may be accessed through the “Events” page of t

  • GlobeNewswire

    Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor

    – Preliminary Data Support Progression to Phase 2a Proof of Concept Trials in T cell-mediated Autoimmune Diseases – WAYNE, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced positive results from ATI-2138-PKPD-102, a Phase 1 Multiple Ascending Dose (MAD) trial of the investigational compound ATI-2138. Preliminary data from the MA